• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

To improve the patient-centeredness of care, patient-reported outcomes have been
increasingly used to quantify patients' symptoms, function, and quality of life. In heart failure …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors
improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in …

Background: Poor health-related quality of life (HRQL) is common in heart failure (HF), but
there are few data on HRQL in HF and the association between HRQL and mortality outside …

Background: Patients hospitalized for acute heart failure experience poor health status,
including a high burden of symptoms and physical limitations, and poor quality of life. SGLT2 …

Background Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to
reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes …

Background Improving symptoms is a primary treatment goal in patients with obstructive
hypertrophic cardiomyopathy. Currently available pharmacological options for hypertrophic …

Elevated levels of diastolic BP and especially systolic BP (SBP) are major risk factors for the
development of HF. 18, 19 One of the most impactful observations from the Framingham …

The recommendations listed in this document are, whenever possible, evidence based. An
extensive evidence review was conducted through October 2011 and includes selected …